Ellevest Inc’s VistaGen Therapeutics VTGN Stock Holding History

Ellevest Inc’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11	Closed	-$33	–	2074
2022 Q4	$33	Buy	+11	New	+$41	﹤0.01%	1800

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ellevest Inc's VTGN Position: Q1 2023 in Review

Ellevest Inc sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 11 shares — an estimated $33 sold.

Ellevest Inc first reported a position in VTGN in Q4 2022 and held it in 1 quarter. The position peaked at $33 in Q4 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

Ellevest Inc reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
Ellevest Inc sold 11 VistaGen Therapeutics shares in Q1 2023, an estimated $33.
Ellevest Inc first reported a position in VistaGen Therapeutics in Q4 2022 and held it in 1 quarter.
Ellevest Inc's VistaGen Therapeutics position peaked at $33 in Q4 2022.
83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.